Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

ARRY 5.94 +0.10 (1.71%)
price chart
Redmile Group - Llc Purchased 49900 shares of Array Biopharma Inc (NASDAQ:ARRY ...
The insider of Array Biopharma Inc (NASDAQ:ARRY) 5.94 +0.10 1.71% , Redmile Group - Llc in the last few days spent exactly $273,452 U.S.
Array BioPharma Inc. (NASDAQ:ARRY) Price Target Update  Money Flow Index
Array BioPharma Inc. (NASDAQ:ARRY) Analyst Rating in Focus  Investor Newswire
Zacks Short Term Rating on Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. (NASDAQ:ARRY) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1 by 7 Wall Street Analysts.
Redmile Group Fortifies Position In Array Biopharma Inc (ARRY); Broadwood ...  Insider Monkey (blog)
Shares of Array BioPharma Inc. (NASDAQ:ARRY) Drops by -4.39%  News Watch International
Biotech Stocks to Love: Illumina, Inc. (ILMN), Array Biopharma Inc (ARRY ...
Array Biopharma Inc (NASDAQ:ARRY) ended at $5.84 by gaining 2.82%. The $807.54M company on August 3, 2015 reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.
Scorching Hot Biotech Stocks Tape - Array Biopharma Inc (NASDAQ:ARRY), Vertex ...
Array Biopharma Inc (NASDAQ:ARRY) advanced 2.82% to end last trading session at $5.84. The company, on August 3, 2015, reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.
Biotech Stocks Buzz: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ...  Wall Street Point
Array BioPharma Inc. Price Target Update
Array BioPharma Inc. (NASDAQ:ARRY) should head towards $11.08 per share according to 6 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $9 per share.
Biotech Stocks to bet on: Galena Biopharma Inc (GALE), Array Biopharma Inc ...
On the trading floor, shares of Array Biopharma Inc (NASDAQ:ARRY) gained 3.82% to close at $5.43. The $722.93M company on July 22, 2015 announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of ...
Biotech Stocks in News Buzz: Sequenom Inc. (NASDAQ:SQNM), Galena Biopharma ...  Seneca Globe
Why Shares in Array BioPharma, Inc. Are Soaring Higher
What: Shares in Array BioPharma (NASDAQ:ARRY) are rallying by more than 10% after the company released its first quarter financial results and offered up insight into its pipeline.
Cantor Fitzgerald Remains Positive on Array Biopharma Inc Following ...  Smarter Analyst
Array Biopharma Shares Jump After Q3 Results  Benzinga
Zacks Rating on Array BioPharma Inc.
Array BioPharma Inc. (NASDAQ:ARRY) remains a strong buy in the latest set of rankings. The shares have received an average rating of 1 by 7 analysts.
Array BioPharma Inc. (NASDAQ:ARRY) Short Interest Update  Insider Trading Report
Short Interest Update on Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. (NASDAQ:ARRY) has witnessed a drop of 0.9% or 227,716 shares in its short figure. The short interest diminution took it from 26,235,056 on July 15,2015 to 26,007,340 on July 31,2015.
Stock in Focus - Array BioPharma Inc. (NASDAQ:ARRY)  Vanguard Tribune
Healthcare Sector Movers: Array BioPharma Inc. (ARRY), Fluidigm Corporation ...  WallStreet Scope
Company Shares of Array BioPharma Inc. Drops by -10.55%
Array BioPharma Inc. (NASDAQ:ARRY) has lost 10.55% during the past week and dropped 16.69% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 8.53%.
Array Biopharma Cut to "Sell" at Zacks (ARRY)  The Legacy
Healthcare Sector Movers: Array BioPharma Inc. (ARRY), Synthetic Biologics ...  WallStreet Scope